137 related articles for article (PubMed ID: 38537343)
1. An all-in-one therapeutic platform for the treatment of resistant Helicobacter pylori infection.
Sun C; Huang J; Guo X; Zhang C; Wei L; Wong KI; Yang Z; Zhao G; Lu M; Yao W
Biomaterials; 2024 Jul; 308():122540. PubMed ID: 38537343
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis.
Arenas A; Serrano C; Quiñones L; Harris P; Sandoval M; Lavanderos M; Sepúlveda R; Maquilón S; Echeverría A; Ríos C; Fuentes-López E; Rojas L; Jorquera A; Pizarro M; Camargo MC; Riquelme A
Sci Rep; 2019 Dec; 9(1):20070. PubMed ID: 31882676
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
[TBL] [Abstract][Full Text] [Related]
4. Dual Clarithromycin and Metronidazole Resistance Is the Main Cause of Failure in Ultimate Helicobacter pylori Eradication.
Hwang JY; Kim C; Kwon YH; Lee JE; Jeon SW; Nam SY; Seo AN; Han MH; Park JH
Dig Dis; 2021; 39(5):451-461. PubMed ID: 33429397
[TBL] [Abstract][Full Text] [Related]
5. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
Lu B; Wang J; Li J; Liu L; Chen Y
Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194
[TBL] [Abstract][Full Text] [Related]
6. Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides.
Kocsmár É; Buzás GM; Szirtes I; Kocsmár I; Kramer Z; Szijártó A; Fadgyas-Freyler P; Szénás K; Rugge M; Fassan M; Kiss A; Schaff Z; Röst G; Lotz G
Nat Commun; 2021 Apr; 12(1):2255. PubMed ID: 33859206
[TBL] [Abstract][Full Text] [Related]
7. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis.
Ko SW; Kim YJ; Chung WC; Lee SJ
Helicobacter; 2019 Apr; 24(2):e12565. PubMed ID: 30698318
[TBL] [Abstract][Full Text] [Related]
8. Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study.
Romano M; Gravina AG; Nardone G; Federico A; Dallio M; Martorano M; Mucherino C; Romiti A; Avallone L; Granata L; Priadko K; Compare D; Tuccillo C; Romito MR; Sgambato D; Miranda A; Romano L; Loguercio C; Bazzoli F; Zagari RM
Helicobacter; 2020 Aug; 25(4):e12694. PubMed ID: 32314519
[TBL] [Abstract][Full Text] [Related]
9. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Kim JL; Cho SJ; Chung SJ; Lee A; Choi J; Chung H; Kim SG
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00194. PubMed ID: 33094958
[TBL] [Abstract][Full Text] [Related]
10. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study.
Yi DM; Yang TT; Chao SH; Li YX; Zhou YL; Zhang HH; Lan L; Zhang YW; Wang XM; Zhang YR; Li J; Ding SZ
Medicine (Baltimore); 2019 Feb; 98(6):e14408. PubMed ID: 30732192
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection.
Liu Q; Qi D; Kang J; Jin Y; Liu W; Gao W; Hou P; Lu J
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):221-5. PubMed ID: 25629566
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study.
Ergül B; Doğan Z; Sarikaya M; Filik L
Helicobacter; 2013 Dec; 18(6):454-8. PubMed ID: 24011287
[TBL] [Abstract][Full Text] [Related]
14. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?
Kutluk G; Tutar E; Bayrak A; Volkan B; Akyon Y; Celikel C; Ertem D
Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1202-8. PubMed ID: 25171023
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant
Kim JJE; Kocsmár I; Buzás GM; Szirtes I; Rusz O; Diczházi C; Szijártó A; Hritz I; Schaff Z; Kiss A; Kocsmár É; Lotz G
Pathol Oncol Res; 2021; 27():1609863. PubMed ID: 34267605
[TBL] [Abstract][Full Text] [Related]
16. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
[TBL] [Abstract][Full Text] [Related]
17. Toward population specific and personalized treatment of Helicobacter pylori infection.
Liou JM; Chen PY; Kuo YT; Wu MS;
J Biomed Sci; 2018 Oct; 25(1):70. PubMed ID: 30285834
[TBL] [Abstract][Full Text] [Related]
18. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
Kim SB; Lee SH; Kim KO; Jang BI; Kim TN
Korean J Gastroenterol; 2015 Nov; 66(5):261-7. PubMed ID: 26586348
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of second-line regimens for
Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
[TBL] [Abstract][Full Text] [Related]
20. Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride.
Williams MP; Hamilton MR; Sercombe JC; Pounder RE
Aliment Pharmacol Ther; 1997 Aug; 11(4):705-10. PubMed ID: 9305479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
